Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.

Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U.

J Med Genet. 2016 Nov 10. pii: jmedgenet-2016-104178. doi: 10.1136/jmedgenet-2016-104178. [Epub ahead of print]

2.

Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.

Pchelina S, Emelyanov A, Baydakova G, Andoskin P, Senkevich K, Nikolaev M, Miliukhina I, Yakimovskii A, Timofeeva A, Fedotova E, Abramycheva N, Usenko T, Kulabukhova D, Lavrinova A, Kopytova A, Garaeva L, Nuzhnyi E, Illarioshkin S, Zakharova E.

Neurosci Lett. 2017 Jan 1;636:70-76. doi: 10.1016/j.neulet.2016.10.039.

PMID:
27780739
3.

Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration.

Janssen CI, Kiliaan AJ.

Prog Lipid Res. 2014 Jan;53:1-17. doi: 10.1016/j.plipres.2013.10.002. Review.

PMID:
24334113
4.

Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease.

Wu G, Pang S, Feng X, Zhang A, Li J, Gu K, Huang J, Dong H, Yan B.

Neurosci Lett. 2011 Aug 1;500(1):31-5. doi: 10.1016/j.neulet.2011.05.238.

PMID:
21683120
5.

Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.

Wu G, Huang J, Feng X, Zhang A, Li J, Pang S, Gu K, Dong H, Zhang J, Gao H, Yan B.

Neurochem Res. 2011 Oct;36(10):1939-44. doi: 10.1007/s11064-011-0516-0.

PMID:
21643977
6.

Investigating variability in patient response to treatment--a case study from a replicate cross-over study.

Senn S, Rolfe K, Julious SA.

Stat Methods Med Res. 2011 Dec;20(6):657-66. doi: 10.1177/0962280210379174.

PMID:
20739334
7.
8.
9.

Therapy adherence issues in Parkinson's disease.

Grosset D; European PD Therapy Compliance Study Group..

J Neurol Sci. 2010 Feb 15;289(1-2):115-8. doi: 10.1016/j.jns.2009.08.053. Review.

PMID:
19793590
10.

Dopamine agonists and therapy compliance.

Grosset D.

Neurol Sci. 2008 Dec;29 Suppl 5:S375-6. doi: 10.1007/s10072-008-1050-y. Review.

PMID:
19381766
11.

Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG.

Mov Disord. 2009 Mar 15;24(4):500-8. doi: 10.1002/mds.22108.

PMID:
19117369
12.

Timing the initiation of treatment in Parkinson's disease.

Grosset DG, Schapira AH.

J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):615. doi: 10.1136/jnnp.2008.144741. No abstract available.

PMID:
18487552
13.

Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.

Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG.

Nucl Med Commun. 2006 Dec;27(12):933-7.

PMID:
17088677
14.

Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT.

Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG.

Mov Disord. 2006 Dec;21(12):2247-50.

PMID:
17078059
15.

Problematic gambling on dopamine agonists: Not such a rarity.

Grosset KA, Macphee G, Pal G, Stewart D, Watt A, Davie J, Grosset DG.

Mov Disord. 2006 Dec;21(12):2206-8.

PMID:
17013907
16.

Measuring therapy adherence in Parkinson's disease: a comparison of methods.

Grosset KA, Bone I, Reid JL, Grosset D.

J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):249-51.

17.

Keynote review: phosphodiesterase-4 as a therapeutic target.

Houslay MD, Schafer P, Zhang KY.

Drug Discov Today. 2005 Nov 15;10(22):1503-19. Review.

PMID:
16257373
18.

Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients.

Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K.

Mov Disord. 2005 Dec;20(12):1598-603.

PMID:
16114020
19.

Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease.

Grosset KA, Reid JL, Grosset DG.

Mov Disord. 2005 Nov;20(11):1397-404. Review.

PMID:
16092116
20.

Spheramine Titan/Schering.

Grosset D, Grosset K.

Curr Opin Investig Drugs. 2005 Jul;6(7):722-8. Review.

PMID:
16044669
Items per page

Supplemental Content

Loading ...
Support Center